Nuveen LLC Invests $1.17 Million in Arvinas, Inc. $ARVN

Nuveen LLC acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 166,597 shares of the company's stock, valued at approximately $1,170,000. Nuveen LLC owned about 0.23% of Arvinas as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of ARVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Arvinas by 3.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,514 shares of the company's stock valued at $700,000 after purchasing an additional 1,353 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Arvinas during the fourth quarter valued at $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Arvinas by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company's stock valued at $8,311,000 after buying an additional 3,047 shares during the period. Rhumbline Advisers grew its position in Arvinas by 3.8% during the first quarter. Rhumbline Advisers now owns 91,210 shares of the company's stock valued at $640,000 after buying an additional 3,333 shares during the period. Finally, Hsbc Holdings PLC grew its position in Arvinas by 22.7% during the fourth quarter. Hsbc Holdings PLC now owns 19,220 shares of the company's stock valued at $365,000 after buying an additional 3,551 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.

Insider Transactions at Arvinas

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of Arvinas stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the sale, the chief financial officer owned 164,401 shares of the company's stock, valued at $1,251,091.61. The trade was a 3.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.73% of the stock is currently owned by company insiders.

Arvinas Trading Up 2.9%

NASDAQ:ARVN traded up $0.22 during trading hours on Friday, reaching $7.83. 1,891,283 shares of the company were exchanged, compared to its average volume of 1,457,613. The stock's 50-day moving average is $7.50 and its 200-day moving average is $8.41. The firm has a market cap of $574.86 million, a PE ratio of -7.75 and a beta of 2.38. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.03. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The company had revenue of $22.40 million for the quarter, compared to analysts' expectations of $34.42 million. During the same quarter in the previous year, the company posted ($0.49) EPS. The firm's quarterly revenue was down 70.7% on a year-over-year basis. As a group, research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. UBS Group dropped their price target on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Guggenheim dropped their price target on shares of Arvinas from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Morgan Stanley dropped their price target on shares of Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. Leerink Partners restated a "market perform" rating and set a $9.00 price target (down previously from $10.00) on shares of Arvinas in a research report on Monday, June 2nd. Finally, Leerink Partnrs lowered shares of Arvinas from a "strong-buy" rating to a "hold" rating in a research report on Sunday, June 1st. Twelve equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.76.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.